Astrocytic activation and an inhibition of MAP kinases are required for proteinase-activated receptor-2-mediated protection from neurotoxicity

Journal of Neurochemistry

Volumn 113, Issue 6, 2010, Pages 1471-1480

  Greenwood, Sam M ^a   Bushell, Trevor J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Astrocyte; Chemokine; MAP kinase; Metabotropic glutamate receptor; Neuroprotection; Proteinase activated receptor 2

Indexed keywords

2 [4 (2 METHYLPROPYL)PHENYL] N METHYLSULFONYLPROPANAMIDE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; FLUOROACETIC ACID; KAINIC ACID; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROTRANSMITTER; PEPTIDE; PROTEINASE ACTIVATED RECEPTOR 2; SERYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCINAMIDE; TRYPSIN; UNCLASSIFIED DRUG; UO 126;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN SLICE; CELL ACTIVATION; CELL DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; ENZYME INHIBITION; HIPPOCAMPUS; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; TISSUE CULTURE;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BUTADIENES; CELL DEATH; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGONISTS; HIPPOCAMPUS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; NITRILES; OLIGOPEPTIDES; ORGAN CULTURE TECHNIQUES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; TRYPSIN;

EID: 77953102949     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06737.x     Document Type: Article

References (68)

1. Afkhami-Goli A., Noorbakhsh F., Keller A. J. et al. (2007) Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J. Immunol. 179, 5493 5503.
2. Alessandrini A., Namura S., Moskowitz M. A. Bonventre J. V. (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl Acad. Sci. USA 96, 12866 12869.
3. Araque A. (2008) Astrocytes process synaptic information. Neuron Glia Biol. 4, 3 10.
4. Araque A., Sanzgiri R. P., Parpura V. Haydon P. G. (1998) Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons. J. Neurosci. 18, 6822 6829.
5. Baskys A. Blaabjerg M. (2005) Understanding regulation of nerve cell death by mGluRs as a method for development of successful neuroprotective strategies. J. Neurol. Sci. 229-230, 201 209.
6. de Bernardo S., Canals S., Casarejos M. J., Solano R. M., Menendez J. Mena M. A. (2004) Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. J. Neurochem. 91, 667 682.
7. Borsello T. Forloni G. (2007) JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des. 13, 1875 1886.
8. Bruno V., Battaglia G., Copani A., D'Onofrio M., Di Iorio P., De Blasi A., Melchiorri D., Flor P. J. Nicoletti F. (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 21, 1013 1033.
9. Bushell T. (2007) The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders. J. Physiol. 581, 7 16.
10. Bushell T. J., Plevin R., Cobb S. Irving A. J. (2006) Characterization of proteinase-activated receptor 2 signalling and expression in rat hippocampal neurons and astrocytes. Neuropharmacology 50, 714 725.
11. Chu C. T., Levinthal D. J., Kulich S. M., Chalovich E. M. DeFranco D. B. (2004) Oxidative neuronal injury. The dark side of ERK1/2. Eur. J. Biochem. 271, 2060 2066.
12. Cottrell G. S., Amadesi S., Schmidlin F. Bunnett N. (2003) Protease-activated receptor 2: activation, signalling and function. Biochem. Soc. Trans. 31, 1191 1197.
13. Cruz C. D. Cruz F. (2007) The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr. Neuropharmacol. 5, 244 252.
14. D'Andrea M. R., Derian C. K., Leturcq D. et al. (1998) Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J. Histochem. Cytochem. 46, 157 164.
15. Fiacco T. A. McCarthy K. D. (2004) Intracellular astrocyte calcium waves in situ increase the frequency of spontaneous AMPA receptor currents in CA1 pyramidal neurons. J. Neurosci. 24, 722 732.
16. Fiacco T. A., Agulhon C., Taves S. R., Petravicz J., Casper K. B., Dong X., Chen J. McCarthy K. D. (2007) Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory synaptic activity. Neuron 54, 611 626.
17. Fiacco T. A., Agulhon C. McCarthy K. D. (2009) Sorting out astrocyte physiology from pharmacology. Annu. Rev. Pharmacol. Toxicol. 49, 151 174.
18. Fonnum F., Johnsen A. Hassel B. (1997) Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Glia 21, 106 113.
19. Gan J., Greenwood S. M., Cobb S. R. Bushell T. J. (2008) Activation of protease activated receptor 2 inhibits hippocampal synaptic transmission. FENS abstracts 115.7.
20. Goldshmidt A. Traynelis S. F. (2006) Four-dimensional imaging reveals effects of PAR-2 agonists on cell morphology and process motility in primary microglia. Abstr. Soc. Neurosci. 386.9.
21. Halassa M. M., Fellin T. Haydon P. G. (2009) Tripartite synapses: roles for astrocytic purines in the control of synaptic physiology and behavior. Neuropharmacology 57, 343 346.
22. Harper S. J. Wilkie N. (2003) MAPKs: new targets for neurodegeneration. Expert Opin. Ther. Targets 7, 187 200.
23. Henneberger C., Papouin T., Oliet S. H. Rusakov D. A. (2010) Long-term potentiation depends on release of D-serine from astrocytes. Nature 463, 232 236.
24. Hetman M. Gozdz A. (2004) Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur. J. Biochem. 271, 2050 2055. (Pubitemid 38747973)
25. Hunot S., Vila M., Teismann P., Davis R. J., Hirsch E. C., Przedborski S., Rakic P. Flavell R. A. (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 665 670.
26. Hyman B. T., Elvhage T. E. Reiter J. (1994) Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am. J. Pathol. 144, 565 572.
27. Jin G., Hayashi T., Kawagoe J., Takizawa T., Nagata T., Nagano I., Syoji M. Abe K. (2005) Deficiency of PAR-2 gene increases acute focal ischemic brain injury. J. Cereb. Blood Flow Metab. 25, 302 313.
28. Johnson G. L. Nakamura K. (2007) The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim. Biophys. Acta 1773, 1341 1348.
29. Kingston A. E., Ornstein P. L., Wright R. A., Johnson B. G., Mayne N. G., Burnett J. P., Belagaje R., Wu S. Schoepp D. D. (1998) LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37, 1 12.
30. Kulich S. M. Chu C. T. (2001) Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 77, 1058 1066.
31. Lee C. J., Mannaioni G., Yuan H., Woo D. H., Gingrich M. B. Traynelis S. F. (2007) Astrocytic control of synaptic NMDA receptors. J. Physiol. 581, 1057 1081.
32. Lohman R. J., O'Brien T. J. Cocks T. M. (2008) Protease-activated receptor-2 regulates trypsin expression in the brain and protects against seizures and epileptogenesis. Neurobiol. Dis. 30, 84 93.
33. Lohman R. J., Jones N. C., O'Brien T. J. Cocks T. M. (2009) A regulatory role for protease-activated receptor-2 in motivational learning in rats. Neurobiol. Learn. Mem. 92, 301 309.
34. Luo W., Wang Y. Reiser G. (2007) Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res. Rev. 56, 331 345.
35. Macfarlane S. R., Seatter M. J., Kanke T., Hunter G. D. Plevin R. (2001) Proteinase-activated receptors. Pharmacol. Rev. 53, 245 282.
36. Miloso M., Scuteri A., Foudah D. Tredici G. (2008) MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases. Curr. Med. Chem. 15, 538 548.
37. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., Davis R. J., Shirasaki Y. Greenberg M. E. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551 7560.
38. Namkung W., Yoon J. S., Kim K. H. Lee M. G. (2008) PAR2 exerts local protection against acute pancreatitis via modulation of MAP kinase and MAP kinase phosphatase signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G886 894.
39. Noorbakhsh F., Vergnolle N., McArthur J. C., Silva C., Vodjgani M., Andrade-Gordon P., Hollenberg M. D. Power C. (2005) Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J. Immunol. 174, 7320 7329.
40. Noorbakhsh F., Tsutsui S., Vergnolle N. et al. (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203, 425 435.
41. Nozaki K., Nishimura M. Hashimoto N. (2001) Mitogen-activated protein kinases and cerebral ischemia. Mol. Neurobiol. 23, 1 19.
42. Okada-Ogawa A., Suzuki I., Sessle B. J. et al. (2009) Astroglia in medullary dorsal horn (trigeminal spinal subnucleus caudalis) are involved in trigeminal neuropathic pain mechanisms. J. Neurosci. 29, 11161 11171.
43. Ossovskaya V. S. Bunnett N. W. (2004) Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84, 579 621.
44. Park G. H., Ryu J. R., Shin C. Y., Choi M. S., Han B. H., Kim W. K., Kim H. C. Ko K. H. (2006) Evidence that protease-activated receptor-2 mediates trypsin-induced reversal of stellation in cultured rat astrocytes. Neurosci. Res. 54, 15 23.
45. Park G. H., Jeon S. J., Ryu J. R. et al. (2009) Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes. Nitric Oxide 21, 110 119.
46. Perea G. Araque A. (2007) Astrocytes potentiate transmitter release at single hippocampal synapses. Science 317, 1083 1086.
47. Pompili E., Nori S. L., Geloso M. C., Guadagni E., Corvino V., Michetti F. Fumagalli L. (2004) Trimethyltin-induced differential expression of PAR subtypes in reactive astrocytes of the rat hippocampus. Brain Res. Mol. Brain Res. 122, 93 98.
48. Rebola N., Rodrigues R. J., Oliveira C. R. Cunha R. A. (2005) Different roles of adenosine A1, A2A and A3 receptors in controlling kainate-induced toxicity in cortical cultured neurons. Neurochem. Int. 47, 317 325.
49. Riek-Burchardt M., Striggow F., Henrich-Noack P., Reiser G. Reymann K. G. (2002) Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. Neurosci. Lett. 329, 181 184.
50. +-dependent glutamate release. Neuroscience 158, 253 259.
51. Sharma A., Tao X., Gopal A., Ligon B., Andrade-Gordon P., Steer M. L. Perides G. (2005) Protection against acute pancreatitis by activation of protease-activated receptor-2. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G388 395.
52. Shigetomi E., Bowser D. N., Sofroniew M. V. Khakh B. S. (2008) Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. J. Neurosci. 28, 6659 6663.
53. Smith-Swintosky V. L., Cheo-Isaacs C. T., D'Andrea M. R., Santulli R. J., Darrow A. L. Andrade-Gordon P. (1997) Protease-activated receptor-2 (PAR-2) is present in the rat hippocampus and is associated with neurodegeneration. J. Neurochem. 69, 1890 1896.
54. Stone T. W., Ceruti S. Abbracchio M. P. (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb. Exp. Pharmacol. 193, 535 587.
55. Striggow F., Riek-Burchardt M., Kiesel A., Schmidt W., Henrich-Noack P., Breder J., Krug M., Reymann K. G. Reiser G. (2001) Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur. J. Neurosci. 14, 595 608.
56. Suo Z., Wu M., Citron B. A., Palazzo R. E. Festoff B. W. (2003) Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling. J. Biol. Chem. 278, 37681 37689.
57. Turner C. P., Yan H., Schwartz M., Othman T. Rivkees S. A. (2002) A1 adenosine receptor activation induces ventriculomegaly and white matter loss. Neuroreport 13, 1199 1204.
58. Turner C. P., Seli M., Ment L., Stewart W., Yan H., Johansson B., Fredholm B. B., Blackburn M. Rivkees S. A. (2003) A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc. Natl Acad. Sci. USA 100, 11718 11722.
59. Turner C. P., Blackburn M. R. Rivkees S. A. (2004) A1 adenosine receptors mediate hypoglycemia-induced neuronal injury. J. Mol. Endocrinol. 32, 129 144.
60. Ubl J. J., Vohringer C. Reiser G. (1998) Co-existence of two types of [Ca2 + ]i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells. Neuroscience 86, 597 609.
61. Wang H., Ubl J. J. Reiser G. (2002) Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 37, 53 63.
62. Wang Y., Luo W. Reiser G. (2007a) Activation of protease-activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth-regulated oncogene/cytokine-induced neutrophil chemoattractant family. Eur. J. Neurosci. 26, 3159 3168.
63. Wang Y., Luo W. Reiser G. (2007b) Proteinase-activated receptor-1 and -2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain. Biochem. J. 401, 65 78.
64. Wang Y., Luo W. Reiser G. (2007c) The role of calcium in protease-activated receptor-induced secretion of chemokine GRO/CINC-1 in rat brain astrocytes. J. Neurochem. 103, 814 819.
65. Yang D. D., Kuan C. Y., Whitmarsh A. J., Rincon M., Zheng T. S., Davis R. J., Rakic P. Flavell R. A. (1997) Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389, 865 870.
66. Zhang J. M., Wang H. K., Ye C. Q., Ge W., Chen Y., Jiang Z. L., Wu C. P., Poo M. M. Duan S. (2003) ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. Neuron 40, 971 982.
67. Zhu X., Lee H. G., Raina A. K., Perry G. Smith M. A. (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11, 270 281.
68. Zhuang S. Schnellmann R. G. (2006) A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319, 991 997.